PMID- 30317679
OWN - NLM
STAT- MEDLINE
DCOM- 20190724
LR  - 20190724
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 33
IP  - 3
DP  - 2019 Mar
TI  - Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis 
      patients: a multicentre retrospective study.
PG  - 553-559
LID - 10.1111/jdv.15288 [doi]
AB  - BACKGROUND: Ixekizumab (anti-IL17A) is effective as treatment for 
      moderate-to-severe plaque psoriasis, but real-life data on effectiveness and 
      safety are currently very limited. OBJECTIVE: To evaluate the efficacy and safety 
      of ixekizumab in a cohort of real-life plaque psoriasis patients. METHODS: 
      Retrospective chart review of 100 patients with moderate-to-severe plaque 
      psoriasis treated with ixekizumab at seven Spanish dermatological centres. 
      RESULTS: According to the as observed analysis, the percentage of patients 
      achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area 
      and Severity Index (PASI) was 87.5%-50.0% at week 12-16; 88.3%-58.4% at week 24 
      and 82.9%-58.5% at week 52, respectively. The mean +/- standard deviation (SD) 
      score of PASI at baseline was 12.9 +/- 9.2, and it declined rapidly after 
      ixekizumab administration to 1.9 +/- 4.0 (P < 0.001) at week 12-16 and was 
      maintained at 1.7 +/- 4.1 and 1.8 +/- 2.9 at week 24 and 52, respectively. Ixekizumab 
      response was not affected by clinical variables like body mass index, disease 
      duration or the presence of psoriatic arthritis. However, the bio-naive group 
      showed significantly higher PASI 75 response rate at week 12-16 compared to 
      patients previously exposed to biologic agents (P = 0.037). Twenty-six (26%) 
      patients experienced adverse events (AEs) during the follow-up period, being most 
      of them of mild-to-moderate intensity. The most common AE was local reaction at 
      the site of injection (14/26; 53.8%). At the end of the observational period, 15 
      (15%) patients discontinued ixekizumab treatment due to limited clinical 
      improvement (n = 11), adverse events (n = 3) or lost to follow-up (n = 1) within 
      a mean +/- SD time of 6.0 +/- 3.9 months. CONCLUSION: The present study illustrates 
      the initial experience with ixekizumab in real-world clinical practice confirming 
      its usefulness and safety in the management of plaque psoriasis patients.
CI  - (c) 2018 European Academy of Dermatology and Venereology.
FAU - Deza, G
AU  - Deza G
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Barcelona, Spain.
FAU - Notario, J
AU  - Notario J
AD  - Department of Dermatology, Hospital Universitari de Bellvitge, Hospitalet de 
      Llobregat, Spain.
FAU - Lopez-Ferrer, A
AU  - Lopez-Ferrer A
AD  - Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, 
      Spain.
FAU - Vilarrasa, E
AU  - Vilarrasa E
AD  - Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, 
      Spain.
FAU - Ferran, M
AU  - Ferran M
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Barcelona, Spain.
FAU - Del Alcazar, E
AU  - Del Alcazar E
AD  - Department of Dermatology, Hospital Germans Trias i Pujol, Badalona, Spain.
FAU - Carrascosa, J M
AU  - Carrascosa JM
AD  - Department of Dermatology, Hospital Germans Trias i Pujol, Badalona, Spain.
FAU - Corral, M
AU  - Corral M
AD  - Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain.
FAU - Salleras, M
AU  - Salleras M
AD  - Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain.
FAU - Ribera, M
AU  - Ribera M
AD  - Department of Dermatology, Hospital Parc Tauli, Sabadell, Spain.
FAU - Puig, L
AU  - Puig L
AD  - Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, 
      Spain.
FAU - Pujol, R M
AU  - Pujol RM
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Barcelona, Spain.
FAU - Vidal, D
AU  - Vidal D
AD  - Department of Dermatology, Hospital Moises Broggi, Sant Joan Despi, Spain.
FAU - Gallardo, F
AU  - Gallardo F
AD  - Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions 
      Mediques, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20181113
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 0 (Dermatologic Agents)
RN  - BTY153760O (ixekizumab)
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Biological Products/therapeutic use
MH  - Dermatologic Agents/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Injection Site Reaction/etiology
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
MH  - Retreatment
MH  - Retrospective Studies
MH  - Severity of Illness Index
EDAT- 2018/10/15 06:00
MHDA- 2019/07/25 06:00
CRDT- 2018/10/15 06:00
PHST- 2018/07/12 00:00 [received]
PHST- 2018/09/27 00:00 [accepted]
PHST- 2018/10/15 06:00 [pubmed]
PHST- 2019/07/25 06:00 [medline]
PHST- 2018/10/15 06:00 [entrez]
AID - 10.1111/jdv.15288 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2019 Mar;33(3):553-559. doi: 10.1111/jdv.15288. 
      Epub 2018 Nov 13.